Research Article
Anemia Control in Kidney Transplant Recipients Using Once-Monthly Continuous Erythropoietin Receptor Activator: A Prospective, Observational Study
Table 3
Proportion of patients within Hb target ranges (efficacy population).
| Hb range | Visit window | 7–9a | 7–12 | 7–15 |
| 11-12 g/dL | 20.7% (40/193) | 2.9% (4/137) | 0.0% (0/153) | 11–13 g/dL | 40.4% (78/193) | 21.2% (29/137) | 15.0% (23/153) | 10–12 g/dL | 42.0% (81/193) | 24.1% (33/137) | 14.4% (22/153) | 10–13 g/dL | 64.8% (125/193) | 52.6% (72/137) | 43.1% (66/153) |
|
|
Prespecified evaluation period.
|